Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy
| Autor: | Harun Fajkovic, J.J. Crivelli, Yair Lotan, S.F. Shariat, A. K. Tewari, Luis A. Kluth, Alberto Briganti, Alexandra Kautzky-Willer, Evanguelos Xylinas, Pierre I. Karakiewicz, Karl Pummer, Douglas S. Scherr, Alexander Bachmann, T. Faison, Malte Rieken, Wolfgang Loidl, Christian Seitz |
|---|---|
| Přispěvatelé: | Rieken, M., Kluth, L. A., Xylinas, E., Seitz, C., Fajkovic, H., Karakiewicz, P. I., Lotan, Y., Briganti, A., Loidl, W., Faison, T., Crivelli, J. J., Scherr, D. S., Bachmann, A., Tewari, A. K., Kautzky-Willer, A., Pummer, K., Shariat, S. F. |
| Rok vydání: | 2013 |
| Předmět: |
Male
Biochemical recurrence Cancer Research medicine.medical_specialty Urology medicine.medical_treatment Prostate cancer Retrospective Studie parasitic diseases medicine Humans In patient Proportional Hazards Models Retrospective Studies Aged Prostatectomy business.industry Prostatic Neoplasms Statin nutritional and metabolic diseases food and beverages Middle Aged Prostate-Specific Antigen Statin treatment medicine.disease Radical prostatectomy Surgery carbohydrates (lipids) Oncology Prostatic Neoplasm Proportional Hazards Model lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitor Hydroxymethylglutaryl-CoA Reductase Inhibitors Neoplasm Recurrence Local business Human |
| Zdroj: | Prostate Cancer and Prostatic Diseases. 16:367-371 |
| ISSN: | 1476-5608 1365-7852 |
| Popis: | Background:The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR.Results:Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values â¤0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.Conclusions:In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR. © 2013 Macmillan Publishers Limited All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|